Compare Plby Group Inc (PLBY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Smith & Nephew plc — how do they compare? Plby Group Inc trades at $0.98 (market cap $118.21M), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 93.9× Plby Group Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and Smith & Nephew plc for 121 Days on average.
| PLBY | SNN | |
|---|---|---|
Market Cap | $118.21M | $11.10B |
Volume | 919,783 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $37.17 |
52-Week Low | $0.99 | $26.42 |
Typical Hold Time | 24 Days | 121 Days |
Enterprise Value | $263.80M | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $0.97, down 4.5% today, with a bearish technical outlook despite analyst optimism. The company shows improving fundamentals with revenue stabilizing around $120M and narrowing losses, though it remains unprofitable with negative equity. Recent leadership appointments signal strategic focus on brand growth and licensing expansion.
The stock presents a turnaround opportunity with strong analyst support (75% buy ratings) but carries significant risk from high debt levels and negative shareholder equity. Near-term catalysts depend on execution of the media and experiences strategy, while competitive pressures and cash flow volatility remain concerns.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
